Novacyt S.A. Launch of VersaLab Portable
26 Maggio 2021 - 8:00AM
RNS Non-Regulatory
TIDMNCYT
Novacyt S.A.
26 May 2021
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Launch of VersaLab(TM) Portable
Paris, France and Camberley, UK - 26 May 2021 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces the expansion of its VersaLab(TM)
portfolio with the launch of VersaLab(TM) Portable to provide an
additional level of support in near-patient testing
environments.
VersaLab(TM) was launched in December 2020 to support private
sector testing of infectious diseases, initially focused on
COVID-19. Novacyt added to the VersaLab(TM) portfolio in March 2021
with the launch of VersaLab(TM) mobile processing laboratories.
Novacyt believes that VersaLab(TM) Portable is an important
addition to its commercial strategy as the Company looks to expand
its reach in private sector testing, especially in overseas
markets. The product is a "PCR lab in a box" and as such comes with
all the equipment required to provide near-patient PCR testing
using Novacyt's PROmate(TM) workflow in non-clinical settings, such
as offices and workplaces.
VersaLab(TM) Portable has been designed specifically with a
focus on small to medium organisations, which represent a growing
market opportunity for Novacyt. Other potential applications
include sport events and facilities, education facilities, the
leisure industry, humanitarian bases and retail.
PROmate(TM) is the only rapid direct-to-PCR COVID-19 assay
approved by the Department of Health and Social Care's Technology
Validation Group. PROmate's(TM) unique workflow allows Novacyt to
provide rapid results to patients in under 80 minutes, saving time
and minimising the risk of infection spreading.
Graham Mullis, Chief Executive Officer of Novacyt,
commented:
"When we launched VersaLab(TM) our aim was to bring PCR
technology closer to patients. The initial market response to the
portfolio is encouraging and the Company looks to increase its
promotion during the second half of 2021. With VersaLab(TM)
Portable we can broaden access to affordable testing in areas that
lack the infrastructure of laboratory-based testing whilst still
providing optimum results from gold standard PCR reagents. We
believe that VersaLab(TM) Portable can support organisations,
including small to medium businesses, offer onsite testing as
lockdowns begin to ease internationally."
End
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
Alex.Shaw@fticonsulting.com / Novacyt.group@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information, please refer to the website:
www.novacyt.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEANSSAFDFEFA
(END) Dow Jones Newswires
May 26, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Novacyt (EU:ALNOV)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Novacyt (EU:ALNOV)
Storico
Da Apr 2023 a Apr 2024